Intranasal immunization of guinea pig with trivalent influenza antigen adjuvanted by Cyclamen europaeum tubers extract

Cyclamen europaeum tubers extract (CTE) with concentration commonly used for human rhinosinusitis treatment was tested as mucosal adjuvant in experimental intranasal immunization of guinea pigs with concentrated commercially available influenza trivalent vaccine and subsequent infection with influen...

Full description

Saved in:
Bibliographic Details
Published in:Archives of virology 2019-01, Vol.164 (1), p.243-247
Main Authors: Evseenko, Vasily A., Kolosova, Natalia P., Gudymo, Anderi S., Maltsev, Semion V., Bulanovich, Julia A., Goncharova, Nataliya I., Danilchenko, Natalia V., Marchenko, Vasiliy Y., Susloparov, Ivan M., Ryzhikov, Alexander B.
Format: Article
Language:English
Subjects:
Adjuvants, Immunologic
Administration, Intranasal
Animals
Antigens
Biomedical and Life Sciences
Biomedicine
Brief Report
Cyclamen
Cyclamen - chemistry
Guinea Pigs
Hemagglutinins
Immunization
Infectious Diseases
Influenza
Influenza B
Influenza Vaccines - immunology
Medical Microbiology
Mucosa
Orthomyxoviridae Infections - prevention & control
Plant Extracts - chemistry
Plant Extracts - pharmacology
Rhinosinusitis
Tubers
Vaccines
Virology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cyclamen europaeum tubers extract (CTE) with concentration commonly used for human rhinosinusitis treatment was tested as mucosal adjuvant in experimental intranasal immunization of guinea pigs with concentrated commercially available influenza trivalent vaccine and subsequent infection with influenza strain A/California/04/2009 H1N1pdm. Dual intranasal immunization with vaccine compound consisting of 7.5 µg of each hemagglutinin and 500 µg of CTE in 50 µl induced reciprocal GMT on day 21 after immunization 40 (5-640) against H1N1pdm; 43.20 (5-1280) against H3N2; 10.80 (5-80) against influenza B. Animals with HI titers 1/80 against cell-derived antigen were completely protected against challenge with A/California/04/2009 H1N1pdm09.
ISSN:0304-8608
1432-8798
DOI:10.1007/s00705-018-4023-3